글로벌 하시모토병 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

최근 몇 년 동안 하시모토병 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 세계보건기구(WHO)에 따르면 요오드의 권장 일일 섭취량(RDI)은 하루 150mcg로 건강한 사람의 95% 이상에게 충분한 양이며, 임신 및 수유부는 더 많은 양이 필요합니다. 과도한 요오드 섭취는 이미 하시모토병의 위험에 처한 사람들에게 트리거 역할을 하는 주요 원인입니다. 하시모토병은 많은 사람에게 영향을 미치는 갑상선 질환입니다. 모든 연령대의 누구에게나 발생할 수 있지만 중년 여성에게 가장 흔합니다. 면역 체계가 갑상선을 공격하여 발생합니다. 이 질병을 진단하고 갑상선 호르몬 수치가 정상 이하로 떨어지려면 몇 달 또는 몇 년이 걸릴 수 있습니다. 갑상선 기능 장애의 가족력이 있는 사람들은 하시모토병에 걸릴 가능성이 더 높습니다.

Data Bridge Market Research는 하시모토병 시장이 2021년에 9억 7,369만 달러 규모였으며 2029년까지 1,282.16만 달러에 도달할 것으로 예상되며 2022년에서 2029년까지의 예측 기간 동안 3.50%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

하시모토병은 갑상선에 영향을 미치는 질환입니다. 하시모토병은 만성 림프구성 갑상선염, 하시모토 갑상선염 또는 자가면역성 갑상선염이라고도 합니다. 갑상선은 신체의 거의 모든 대사 활동(음식을 에너지로 전환하는 방식)을 조절하고 유지하는 호르몬을 생성합니다. 하시모토 갑상선염은 면역 체계가 갑상선을 잘못 식별하여 영향을 미치는 자가면역 질환입니다.

보고 범위 및 시장 세분화

하시모토병 시장 동향

운전자

• 갑상선 기능 저하증 유병률 증가

갑상선 기능 저하증의 유병률 증가는 하시모토병 시장의 성장을 촉진할 것으로 추정됩니다. 갑상선이 면역 체계에 의해 손상되면 신체의 필요를 충족시킬 만큼 충분한 갑상선 호르몬을 생산할 수 없어 하시모토 갑상선 기능 저하증이 발생합니다. 갑상선 호르몬은 음식을 에너지로 전환하는 과정인 신진대사를 제어합니다.

• 의료 인프라에 대한 투자 증가

하시모토병 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 인프라를 개선하는 데 도움이 되는 의료비 지출 증가입니다. 또한, 다양한 정부 기관은 자금을 늘려 의료 인프라를 개선하고자 하며, 이는 시장 역학에 더욱 영향을 미칠 것입니다.

• 노령 인구의 증가

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get Hashimoto’s disease, further estimated to enhance the market’s growth rate.

• Surging incidences of autoimmune disease

The increasing incidences of autoimmune disease is anticipated to influence the growth of Hashimoto’s disease market. Rheumatoid arthritis, lupus and type 1 diabetes are among the various autoimmune disease that increases the risk of Hashimoto’s disease and further flourish the markets growth during the forecast period of 2022-2029.

Furthermore, rising initiatives by public and private organizations to spread awareness and family history with thyroid diseases will expand the Hashimoto’s disease market. Additionally, rising radiation exposure and high consumption alcohol and alcohol will result in the expansion of Hashimoto’s disease market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Hashimoto’s disease market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the Hashimoto’s disease market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the Hashimoto’s disease market. Additionally, strict regulatory policies and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This Hashimoto’s disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Hashimoto’s disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

In the United States, Hashimoto's disease is the most frequent cause of hypothyroidism, affecting around 5% of the population. It affects mostly adult females and usually appears between the ages of 40 and 60. Females are at least 8 times more likely than males to be affected.

Hashimoto’s disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hashimoto’s Disease Market

Over the projected period, the Hashimoto’s disease market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The Hashimoto’s disease market has also been hampered by the supply chain slowness.

Global Hashimoto’s Disease Market Scope

The Hashimoto’s disease market is segmented on the basis of type, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Stress Related
• Infection Related
• Autoimmune Related
• Environmental Related
• Disease Related
• Mixed
• Others

Treatment

• T-3 Hormone Replacement Therapy
• T-4 Hormone Replacement Therapy
• Others

Diagnosis

• Antibody Tests
• Testing Thyroid Function
• Thyroxine (T-4) Test
• Thyroid Stimulating Hormone (TSH) Test
• Others

Dosage form

• Tablets
• Capsule
• Powder
• Others

Route of Administration

• Oral
• Topical
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hashimoto’s Disease Market Regional Analysis/Insights

The Hashimoto’s disease market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Hashimoto’s disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the Hashimoto’s disease market because of the growing number of research and development in autoimmune disorders and rising healthcare expenditure in this region. Additionally, the presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to rising population and surging number of generic manufacturers in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hashimoto’s Disease Market Share Analysis

The Hashimoto’s disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Hashimoto’s disease market.

Some of the major players operating in the Hashimoto’s disease market are:

• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Eli Lilly and Company (US)
• Merck & Co., Inc. (US)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Cipla Inc. (US)
• Abbott (US)
• AbbVie Inc. (US)
• Merck KGaA (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma(인도)
• 루팡(인도)
• Provell Pharmaceuticals, LLC(미국)
• 알보젠(미국)
• 피라말 엔터프라이즈 유한회사(미국)
• Dr. Reddy's Laboratories Ltd. (인도)
• 파이저 주식회사(미국)
• Fresenius Kabi AG(독일)
• Bio-Rad Laboratories, Inc. (미국)
• 다케다제약 주식회사(일본)
• 사노피(프랑스)
• F. 호프만-라 로슈 유한회사(스위스)

SKU-53870